SlideShare a Scribd company logo
1 of 52
Download to read offline
ANVISA
National Health Surveillance Agency
PREPARED BY;
GUIDED BY;
ANKIT GOTECHA
Dr. TEJAL MEHTA
13MPH101
PHARMACEUTICS
SEM 1 (M-PHARM)
PHARMACEUTICAL TECHNOLOGY
AND BIOPHARMACEUTICS
Introduction
• ANVISA is regulatory body of BRAZIL. Brazil is biggest
country of South America. Some of the small countries
nearby Brazil are following the rules according to
ANVISA.
• ANVISA means “Agencia Nacional de Vigilancia
Sanitaria”. This abbreviation is in Portuguese language.
In English, it means “National Health Surveillance
Agency” or sometimes it is written as “Brazilian Health
Surveillance Agency”.
•

ANVISA is established on 26th January, 1999. Thus it
does not have long historical backgrounds.

• To get information about ANVISA, one has to open the
website www.anvisa.gov.br. The website will open in
Portuguese language first.
BACKGROUND
• The National Health Surveillance Agency was established in
1999 by president Fernando Henrique Cardoso. Linked to the
Ministry of Health, the agency coordinates:
– The National Sanitary Surveillance System
– The National Program of Blood and Blood Products
– The National Program of Prevention and Control of
Hospital Infections
• Anvisa's Mission
– "To protect and promote health, ensuring the hygiene
and safety of products and services and taking part in
developing access to it."
• Values
– Transparency
– Knowledge (as a springboard for action)
– Cooperation
• Vision
– To be an agent for transformation of the decentralized
sanitary surveillance system, within a network, holding
a distinct position, legitimized by the population, as
regulator and promotor of social well-being.
• ANVISA is responsible for
– monitoring drug prices
– prices of medical devices
– control and inspection of smoking products
– technical support in granting of patents by the National
Institute of Industrial Property.
– protection of the health of the population by exercising
sanitary control over production
– marketing of products and services subject to sanitary
surveillance, controlling ports, airports and borders
– linked to the Brazilian Ministry of Foreign Affairs and foreign
institutions over matters concerning international aspects of
sanitary surveillance.
ANVISA is a part of NSSS
• National System of Sanitary Surveillance (NSSS) is an organization
of Brazil whose responsibility is
– To keep a watch over certain professional activities
– To put a stop to charlatanism
– To inspect ships, cemeteries and places where food was on sale
to the public.
• The federal, state and municipal units of this sanitary surveillance
are:
– National Agency for Sanitary Surveillance (ANVISA)
– The National Council of State Health Secretaries (CONASS)
– The National Council of Municipal Health Secretaries
(CONASEMS)
– The State, Federal District and Municipal Sanitary Surveillance
Centers (VISAS)
– The Central Public Health Laboratories (LACENS)
– The National Institute for Quality Control in Health (INCQS)
– The Oswaldo Cruz Foundation (FIOCRUZ)
– The State, District and Municipal Health Councils
HIGHLIGHTS OF ANVISA
National System of Sanitary Surveillance

• In this section, you will find the addresses (in portuguese) of
the federal, state and municipal units of sanitary surveillance
that make up the National System of Sanitary Surveillance.
Generic Drugs
• FAQs section
• Industry –
– In this section, industry professionals can obtain
information about Brazil's Generic Drugs Policy.
– If your company wishes to apply for registration of a
generic drug, whose reference drug has not yet been
informed by ANVISA, please make a formal request to the
Office of Generic Drugs.
– Pharmaceutical equivalence and bioequivalence tests
needed for registering generic drugs can only be carried
out by reference centers duly authorized by ANVISA.
• Legislation – Rules and documents related to regulation and
registration of drugs in Brazil. Various Guidelines different
categories are given.
Medicine Bioavailability Bioequivalence
Centers
•
•
•
•

Application Forms for BA/BE centers
Certification for Medicine Bioavailability/Bioequivalence Centers
Renewal of Certification for Medicine BA/BE centers
Centers for carrying out BA/BE shall observe the rules and
technical regulations in force.
• BA/BE Good Practices Manual is given in two volumes
Travelers Information
• This section is covered under a specific part of ANVISA related
to Airport and Border regulation. Any new visitor of Brazil has
to take Vaccine against YELLOW FEVER at least 10 days before
his arrival to Brazil. And on arrival he has to show
“International Certificate of Vaccination (ICV)”.
• If he had taken Vaccine against yellow fever, before 10 years,
then he has to take it again a booster dose.
• Anvisa's Public Health Care Centers and Vaccination Rooms (in
Portuguese) are ready to provide the vaccine and to issue the
International Certificate of Vaccination (ICV), which is yellow.
• Every person vaccinated in one of the Sanitary Units of the
Unified Health System (SUS) receives the National Certificate
of Vaccination, which is white and accepted in the whole
country.
• If, after that, you need the ICV, you should go to a Public
Health Care Center or to a Vaccination Room of ANVISA to
copy the National Certificate data to the International one.
Severe Acute Respiratory Syndrome
• In Brazil, there may be probability of getting Severe
Acute Respiratory Syndrome (SARS) disease, similar to
yellow fever. Thus, ANVISA had provided information on
website for it. They had provided WHO website link for
direct information.
OFFICES OF ANVISA
•
•

Advisory Council
Office of Ombudsman
ADVISORY COUNCIL
• It monitors and follows up the development of activities
carried out by ANVISA. Council comprise of Representatives
from…
– Public Administration Institutions
– Organized Civil Society
– Scientific Community
• The main function of advisory council is to provide
information upon request by any citizen, patient, industrialist
or health professional on any topics. Unlike other well known
regulatory bodies, ANVISA does not have specific offices for
each topic to provide specific information only. It has a
general functioning common Advisory council.
OFFICE OF OMBUDSMAN
• It is an independent body for direct communication of Citizens
or Institutes to attend the Complaints.
• It is characterized by impartiality and transparency.
• It has no direct or indirect linking with ANVISA. It is regulated
directly under the Brazilian ministry of health.
• It Start action against complaints within 2 days, if appropriate.
Regulations by ANVISA
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Blood and blood products
Cosmetics
Drugs
Generic Drugs
Food
Health services
International Affairs
Market regulations
Medical devices
Pharmacovigilance
Ports, airports and borders
REBLAS – Brazilian network of Analytical Laboratory
Sanitizing Products
Tobacco
Toxicology
ANVISA - GUIDELINES
REGISTRATION OF NEW DRUG
• Registration procedure of new drug is divided in mainly 3
parts as follows…
1. Pre-registration measures
• Protocol for Clinical study
2 Registration
• Documents to be submitted
• Protocol for the new drug
• Protocol for import of new drug
3 Post-registration
• Alteration in Registration, Renewal of Registration
 Thus, these three parts can be considered similar to IND, NDA
and Supplementary NDA as per US FDA.
I. Pre-registration measures
• In case of a new national drug product, the protocols of the
clinical studies and the results or current status of the studies
in compliance with the legislation in force has to be
submitted.
• In case of a new imported drug product that will undergo
phase III clinical studies in Brazil, the study protocol and the
results or current status of the studies in compliance with the
legislation in force has to be submitted.
• Whenever phase III will take place with a new product
manufactured in the country, pre-notification for the
production of pilot batch according to the GUIDE FOR THE
NOTIFICATION OF PILOT BATCHES OF MEDICINES has to be
submitted.
II. Registration
1. Documents to be submitted
•
•
•
•

Registration petition forms
Proof of payment of Sanitary Surveillance Inspection
copy of the company’s Operation License
Technical Responsibility Certificate by the Regional Pharmacy
Council
• Copy of the notification protocol of pilot batch production
• Good Manufacturing Practices certificate (GMP) emitted by
ANVISA
2. Protocol for the new drug
• General data: package insert text, label etc…
• Expiry date by Stability studies
• All Toxicity study reports
• Clinical trial data with statistical treatments
• For Combination – Maximum 3 is allowed for oral or injectable
preparations. Four combinations are allowed only if the fourth
ingredient is caffeine.
• Retail Price: if the product is available in other market then
applicator has to submit retail price of product to consumer. If
product is not available anywhere, and first time registered in
Brazil, then has to submit the Proposed retail cost of new drug
product.
• Physico-Chemical parameters of drug
• Synthesis route (all reagent, solvent, condition)
• Pharmacodynamic parameters
• Pharmacokinetic parameters
• Production Report(Batch size ,methods and equipments used)
• Q.C. of raw material and finished products
3. Protocol for the import of new drug
 GMP of importing country or Inspection by ANVISA.
 Documentation is allowed in Portuguese, English or
Spanish language.
 Label, Package Insert must be in Portuguese (Brazilian)
language
 Official Documents like certificates given by importing
country, if it is in foreign language that must be translated
with Legal translator only.
 In some cases, applicator wants to import Bulk drug from
foreign and then Pack the product in Brazil. In such cases,
Expiry Date must be counted from Manufacturing date in
foreign, and not the packaging date in Brazil
 Additionally all document should be submitted in CD
III. Post-registration measures
• Any registration changes shall follow the procedures specified
in the GUIDE FOR MAKING POST-REGISTRATION ALTERATIONS
AND INCLUSIONS IN MEDICINES.
• ANVISA may undertake a control analysis of commercialized
batches in official laboratories in order to monitor the quality
and conformity of the drug with the drug registered.
Whenever necessary, ANVISA may request that the
companies train their technicians in order to enable them to
undertake this monitoring.
TECHNICAL REGULATION OF GENERIC
DRUGS
Definition:
• Generic drug product is similar to a reference or innovator
product, expected to be interchangeable with latter, usually
produce after expiration or waiver of patent protection or of
other exclusive rights, and its effectiveness, safety and quality
had been already proven.
• Registration procedure for Generic drug is similar to new drug
registration.
– Pre registration measures
– Registration
– Post registration
Additional Requirements in registration includes…
• Pharmaceutical Equivalence : Generic and Reference
• If anyone of Generic or Reference is Coated tablet, prove that
coating does not present Gastro-protection
• Bioequivalence study in Laboratories duly authorized by
ANVISA
• Exemption of Bioequivalence study
– Based on comparison of dissolution profile
– For BCS Class I product – High solubility & permeability
Medicines NOT accepted as GENERIC
• Parenteral that don’t contain API like WFI, glucose solution,
NaCl solution, electrolytes solution etc.
• Biological products: Blood, Plasma products
• Products obtained through Biotech except antibiotics
• Herbal drug products
• Vitamins &/or Mineral salts
• Antiseptics for Hospital use
• Endogenous Hormones of oral use
• Products with Diagnostic purpose and Radiological contrasts
• Some of OTC products
Similar Drugs
• Similar drugs are similar to Reference Drug product. It has
Same
Concentration,
Dosage
Form,
Route
of
Administration, Strength ,Therapeutic action, but it only
Differs in Size, Form of product, Packaging, Labeling, Expiry
date, Excipients, Vehicles, and it is mainly identified by Trade
Mark / Brand Name.
• The advantage of similar drug is that it can be Dispense in
place of Reference drug, unless denied by Doctor in written
prescription.
 How to identify the types of drugs in the Brazilian market:
generic and branded?
• Generic drug package / box contain phrase“ Generic Drug Law
9.787/99 “
• Generic will be identified in blue large letter “ G “ printed
over a yellow emblem located in the lower part of the
package which carry the product.
Harmonisation of already registered drugs
• ANVISA had introduced some modification in Registration
procedures and Documents after 1st December 2004.
• Drugs Registered before this date, has to submit information
or data or documents related to drug, for harmonization with
Newer Registered drug products
Homeopathic drugs
• Registration of Homeopathic drugs is valid upto 5 years.
• For Injectables Homeopathic medicines, applicator has to
submit Risk/Benefit compared with oral presentation of same
product
• Combination of any synthetic/ semi-synthetic/ biological
product/ vitamins/ mineral salts/ herbal along with
homeopathic is forbidden.
Registration EXEMPTED for…
• Simple drug product (Single Ingredient)
• Without trademark or brand name
• Manufacturing as per Brazilian Homeopathic Pharmacopoeia
• Or in official compendia recognized by ANVISA
Registration REQUIRED for…
• Simple or Compound (2 or more Ingredient)
• With trademark and brand name
• whose formulation is composed of substances of verified
therapeutic action described in the homeopathic drug
product literature, official compendia, clinical studies or
indexed journals and manufacturing procedures are as per
Brazilian Homeopathic Pharmacopoeia
GITE :List of specified therapeutic group and
indications
•
•
•
•
•

Drugs described in GITE can be sold OTC
Parentrals can not sold OTC (can not sell without Prescription)
Drugs not listed in GITE can not sell without PRESCRIPTION.
Any NEW DRUG, not to be sold under GITE
If New Drug has minimum 5 years experience in USA or
European market (with FDA or EMEA approval), and if it
comes under GITE list, applicator may request to classify it as
OTC product.
In-vitro Diagnostic product
ANVISA had classified in vitro diagnostic product into 4 classes as
follows…
Group A - Materials, devices, accessories & inputs for support of in
vitro diagnostic products.
Group B - for diagnosis of non-transmissible diseases.
Group C - for diagnosis of infectious-contagious diseases, except those
classified in Group D.
Group D - for diagnosis of infectious-contagious diseases, sexually
transmissible diseases or diseases spread by blood and blood
products, as well as identification of blood groups, transfusion or
preparation of blood products.
Documents required for Registration…
• Application form, Fee payment receipt
• Copy of License or Permit for Manufacturing.
• Label on the package of product, Instruction for Use
• Technical Report
• If imported, proof of Registration at competent health agency of
importing country
Cosmetics
Four Categories
– Hygiene Product - Soap, Shampoo, Tooth paste…
– Cosmetic – Lipstick, Beauty Creams, Hair dye, Talc, Eye
cosmetics, Nail cosmetics, Sunscreens, Oils…
– Perfume
– Children’s Product
Level of Risk
 Level 1 - Products with minimum risk
 Level 2 - Products with potential risk
• ANVISA is more conscious about cosmetics and thus a
stringent rules and conditions are observed for cosmetics.
• ANVISA gives a List of Allowed PRESERVATIVES (56
preservatives) with the following details of preservatives
 Ref. No.
 Substance Name
 Maximum Allowable Concentration
 Limitations
 Condition of Use and Warning
• Similar to preservatives, ANVISA also gives List of Allowed
SUNSCREEN AGENTS (23) with similar details
• Similarly, List of Allowed COLORING AGENT also given by
ANVISA with following information…
 Name or Number of Coloring Agent
 Colour
 Field of Application : 1 / 2 / 3 / 4
 Other Limitation or Requirements
• Field of Application is important to write for coloring agent.
Classification is…
 Permitted for All Cosmetics
 For All Cosmetics, Except EYE Area
 In Cosmetic which don’t come in contact with Mucosa
 In Cosmetic which come in contact with Skin & Hair only
Briefly
List of RESTRICTIVE SUBSTANCES is also given by ANVISA.
• Restrictive substances can be used with some established
conditions and a specific warning for each individual
restrictive substance should be printed on Label as per
requirement. For such restrictive substance ANVISA had given
following information….
• Ref. No.
• Substance Name, Field of application or use
• Maximum Allowable Concentration
• Limitations and Requirements
• Condition of Use and Warning
List of PROHIBITED SUBSTANCE (412) is also given which cannot
be used in cosmetic products.

For Registration of Cosmetic, one has to enter the CODES in the
application form given in guideline.
• Codes are given for…
 Cosmetic Product Group i.e. Toothpaste, Beauty cream
 For Physical form i.e. Cream, Powder, Aerosol, Gel
 Preservation Care
 Primary Packaging i.e. Al tube, film, vial, jar
 External Packaging i.e. plastic bag, cloth bag, case, jar
GMP
• As per the latest updates of “GMP Guide for Pharmaceutical
Industry” approved by WHO’s World Health Assembly – WHA.
• For Import of Drug in Brazil from country which is not
included in MERCOSUL group requires Inspection of Drug
Manufacturing unit by ANVISA.
• MERCOSUL = Mercado Commun del Sul means “South
Common Market” includes Argentina, Brazil, Chile, Paraguay &
Uruguay (Group of Countries of South America)
• All documents should be submitted in Portuguese language
and Certified by the Brazilian Consulate, of the Country,
where the Drug for Importation in Brazil is manufactured
• GMP Certificate is Valid upto 1 year only.
BA/BE Guidelnes
Three stages of testing
• Clinical Stage
• Follow clinical studies as per Brazilian Pharmacopoeia
• There should be not more than 5% difference in amount of
Test and Reference API
• Clinical researcher has to Quantify Unchanged API and
Metabolites both.
• Interval before 2nd dose – atleast 7 t1/2 of API
• Weight of Volunteer should be +/- 15% of Normal Wt.
• If t1/2 > 24 hrs. – Collect sample upto 72 hrs
• Modified Release DF – Add Study with FOOD
• Protocol approved & licensed by National Committee of Ethics
in Research
Analytical Stage
• As per GCP, GLP ; using SOPs
• Use Enough Std. for Calibration Curve
• Chromatographic Methods are recommended
• NMT 20% samples are Re-analyzed.
• Loss of Samples shall be Justified
• Results below LQL (Lower Quantification Limit) are considered
as ZERO for statistical calculation.
Statistical Stage
• Calculate ASC, Cmax, Tmax. (ASC in Portuguese means AUC in
English)
• For Multiple doses…
– Average Conc. In Steady state
– Fluctuation Rate in Steady state
• Submit – ANOVA, SSR, DF, F value, p value…
• Necessary to build 90% Confidence Interval (CI)
• For Low therapeutic Range API – 95% CI
• Information about Software Program used.
BA – BE GOOD PRACTICE MANUAL
•
•
•
•

Volume I
Module 1. Clinical Step
Module 2. Analytical Step
Module 3. Statistical Step

•
•
•
•

Volume II
Module 1. Micropipettes
Module 2. Water for Chemical Analysis
Module 3. Analytical Instrumentations
OTHER FUNCTIONS OF ANVISA:
REBLAS - Brazilian Network of Analytical Laboratories. It is the
laboratory network and every analysis and clinical studies
must be performing at any one of the REBLAS center
approved by ANVISA.
• Along with Drugs and Cosmetics, ANVISA have also regulation
on…
– Medical devices
– Food
– Tobacco products
– Toxic products
– Pharmacovigilance
RECENT TRENDS OF ANVISA:
• Launched the project to prevent the resistance against Antibiotic drugs
• The site is among the ten best in two categories of the iBest
Awards. ANVISA’s site is among the ten finalists in two
categories i.e. “Government” and “Health and Well-being”
• Launched the project to prevent the resistance against Antibiotic drugs.
INDIAN PHARMA IN BRAZILIAN MARKET:
Prominent product exporters:
• Zydus Cadila
• Torrent Pharmaceuticals
• Dr. Reddys Labs
• Ranbaxy Pharmaceuticals
• Intas Pharmaceuticals
• Sun Pharmaceuticals
Major Drugs exported:
• Losartan Potassium
• Zolpidem tartarate
• Alprazolam
• Enalapril Maleate
• Nortryptiline
• Carbamazepine
• Clonazepam
• Fluconazole
• Fluoxetine, etc.
ANVISA approved CROs in Ahmedabad:
•
•
•
•
•
•
•
•

Accutest
BioArc Research Labs
Zydus Research Center (ZRC)
Torrent Research Center (TRC)
Cadila Pharma
Lambda Research Center
Veeda Research Center
Synchron Research Labs
REFERENCE

www.anvisa.gov.br

THANK YOU
Anvisa gudelines

More Related Content

What's hot

ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA sandeep bansal
 
Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPTDoninder Hooda
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of AuditMegha bhise
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letterSridhar S
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilGaurav Kr
 
FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1Jorge Torres
 
INSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELSINSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELSOORATHI SASIVARDHAN
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
 
EU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSEU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSChandra Mohan
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
regulatory requirement for bioequivalence
regulatory requirement for bioequivalenceregulatory requirement for bioequivalence
regulatory requirement for bioequivalencelamrin33
 
Regulatory requirements-BA/BE Studies
 Regulatory requirements-BA/BE Studies Regulatory requirements-BA/BE Studies
Regulatory requirements-BA/BE StudiesKireeti Bheemavarapu
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european unionbdvfgbdhg
 
ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submissionRohit K.
 

What's hot (20)

ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
 
GHTF
GHTFGHTF
GHTF
 
Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPT
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letter
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazil
 
FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1FDA PreApproval Inspection - Part 1
FDA PreApproval Inspection - Part 1
 
eCTD Submissions
eCTD SubmissionseCTD Submissions
eCTD Submissions
 
INSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELSINSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELS
 
GHTF study group 3
GHTF study group 3GHTF study group 3
GHTF study group 3
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
 
EU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSEU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONS
 
Emea
EmeaEmea
Emea
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
USFDA NDA Vs BLA
USFDA NDA Vs BLAUSFDA NDA Vs BLA
USFDA NDA Vs BLA
 
regulatory requirement for bioequivalence
regulatory requirement for bioequivalenceregulatory requirement for bioequivalence
regulatory requirement for bioequivalence
 
Regulatory requirements-BA/BE Studies
 Regulatory requirements-BA/BE Studies Regulatory requirements-BA/BE Studies
Regulatory requirements-BA/BE Studies
 
ANVISA
ANVISAANVISA
ANVISA
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european union
 
ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submission
 

Viewers also liked

Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013María Inés Guaia
 
Pharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in MexicoPharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in MexicoMaría Inés Guaia
 
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...qserveconference2013
 
Medical Device - ANVISA regulation in Brazil
Medical Device - ANVISA regulation in BrazilMedical Device - ANVISA regulation in Brazil
Medical Device - ANVISA regulation in BrazilSagi Grinshtein
 
Drug registration in Argentina
Drug registration in ArgentinaDrug registration in Argentina
Drug registration in ArgentinaMaría Inés Guaia
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDMahesh shinde
 
Brazil Pharmaceutical Market Indicators 2003-2013
Brazil Pharmaceutical Market Indicators 2003-2013Brazil Pharmaceutical Market Indicators 2003-2013
Brazil Pharmaceutical Market Indicators 2003-2013BrazilPharmaNews.com
 
Centralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africaCentralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africaHarishankar Sahu
 
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTCopp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTSuraj Pamadi
 
Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...inemet
 
The regulation of medicines in Australia
The regulation of medicines in AustraliaThe regulation of medicines in Australia
The regulation of medicines in AustraliaTGA Australia
 
To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...Aakashdeep Raval
 
Cmu experimental design
Cmu experimental designCmu experimental design
Cmu experimental designray4hz
 
Regulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric CountriesRegulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric Countriesshivampharma88
 

Viewers also liked (20)

Anvisa
AnvisaAnvisa
Anvisa
 
Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013
 
Pharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in MexicoPharma Regulatory Affairs in Mexico
Pharma Regulatory Affairs in Mexico
 
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...
 
Medical Device - ANVISA regulation in Brazil
Medical Device - ANVISA regulation in BrazilMedical Device - ANVISA regulation in Brazil
Medical Device - ANVISA regulation in Brazil
 
Drug registration in Mexico
Drug registration in MexicoDrug registration in Mexico
Drug registration in Mexico
 
Drug registration in Argentina
Drug registration in ArgentinaDrug registration in Argentina
Drug registration in Argentina
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTD
 
14. Laura Castanheira - Anvisa
14. Laura Castanheira -  Anvisa14. Laura Castanheira -  Anvisa
14. Laura Castanheira - Anvisa
 
PH in human body
PH in human bodyPH in human body
PH in human body
 
Brazil Pharmaceutical Market Indicators 2003-2013
Brazil Pharmaceutical Market Indicators 2003-2013Brazil Pharmaceutical Market Indicators 2003-2013
Brazil Pharmaceutical Market Indicators 2003-2013
 
Centralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africaCentralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africa
 
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTCopp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
 
Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...
 
The regulation of medicines in Australia
The regulation of medicines in AustraliaThe regulation of medicines in Australia
The regulation of medicines in Australia
 
To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...To compare filing process of NDA of different countries of India, US and Euro...
To compare filing process of NDA of different countries of India, US and Euro...
 
2ª Assembleia 2017 – ANVISA – Medicamentos Genéricos
2ª Assembleia 2017 – ANVISA – Medicamentos Genéricos2ª Assembleia 2017 – ANVISA – Medicamentos Genéricos
2ª Assembleia 2017 – ANVISA – Medicamentos Genéricos
 
Cmu experimental design
Cmu experimental designCmu experimental design
Cmu experimental design
 
RDC Nº 17/2010
RDC Nº 17/2010RDC Nº 17/2010
RDC Nº 17/2010
 
Regulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric CountriesRegulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric Countries
 

Similar to Anvisa gudelines

Latin American Regulations - What you Don't Know
Latin American Regulations - What you Don't KnowLatin American Regulations - What you Don't Know
Latin American Regulations - What you Don't KnowGreenlight Guru
 
Brazil Cosmetics Regulations by Artixio
Brazil Cosmetics Regulations by ArtixioBrazil Cosmetics Regulations by Artixio
Brazil Cosmetics Regulations by ArtixioAndyThomas119
 
Regulatory pharmacovigilance costa rica
Regulatory pharmacovigilance costa ricaRegulatory pharmacovigilance costa rica
Regulatory pharmacovigilance costa ricaMarilu Escorche
 
pharmacovigilance.pptx
pharmacovigilance.pptxpharmacovigilance.pptx
pharmacovigilance.pptxArhumKh1
 
Methods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxMethods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxPankajKadyan5
 
Pharmacovigilance Programs of India PvPi
Pharmacovigilance Programs of India PvPiPharmacovigilance Programs of India PvPi
Pharmacovigilance Programs of India PvPiSachinKumar2160
 
pharmacovigilacne,Dr.HirenR1.pptx
pharmacovigilacne,Dr.HirenR1.pptxpharmacovigilacne,Dr.HirenR1.pptx
pharmacovigilacne,Dr.HirenR1.pptxDrJatinDhanani
 
WHO international drug monitoring programme.pptx
WHO international drug monitoring programme.pptxWHO international drug monitoring programme.pptx
WHO international drug monitoring programme.pptxashharnomani
 
Pharmacovigilance (pv)
Pharmacovigilance (pv)Pharmacovigilance (pv)
Pharmacovigilance (pv)Reena Titoria
 
pharmacovigilance pdf (1)
pharmacovigilance pdf (1)pharmacovigilance pdf (1)
pharmacovigilance pdf (1)Prasad Bhat
 
Pharmacovigilance pdf (1)
Pharmacovigilance pdf (1)Pharmacovigilance pdf (1)
Pharmacovigilance pdf (1)Prasad Bhat
 
Pharmacovigilance of Natural Drugs- Durgashree Diwakr
Pharmacovigilance of Natural Drugs- Durgashree  DiwakrPharmacovigilance of Natural Drugs- Durgashree  Diwakr
Pharmacovigilance of Natural Drugs- Durgashree DiwakrDurgashree Diwakar
 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reportingSONALPANDE5
 
Market Access Database Spain 2013
Market Access Database Spain 2013Market Access Database Spain 2013
Market Access Database Spain 2013Josep Darba
 
Minimum requirements for a functional pharmacovigilance system
Minimum requirements for a functional pharmacovigilance systemMinimum requirements for a functional pharmacovigilance system
Minimum requirements for a functional pharmacovigilance systemPriti Gupta
 

Similar to Anvisa gudelines (20)

Latin American Regulations - What you Don't Know
Latin American Regulations - What you Don't KnowLatin American Regulations - What you Don't Know
Latin American Regulations - What you Don't Know
 
Anvisa
AnvisaAnvisa
Anvisa
 
Brazil Cosmetics Regulations by Artixio
Brazil Cosmetics Regulations by ArtixioBrazil Cosmetics Regulations by Artixio
Brazil Cosmetics Regulations by Artixio
 
Regulatory pharmacovigilance costa rica
Regulatory pharmacovigilance costa ricaRegulatory pharmacovigilance costa rica
Regulatory pharmacovigilance costa rica
 
pharmacovigilance.pptx
pharmacovigilance.pptxpharmacovigilance.pptx
pharmacovigilance.pptx
 
Methods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxMethods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Pharmacovigilance Programs of India PvPi
Pharmacovigilance Programs of India PvPiPharmacovigilance Programs of India PvPi
Pharmacovigilance Programs of India PvPi
 
pharmacovigilacne,Dr.HirenR1.pptx
pharmacovigilacne,Dr.HirenR1.pptxpharmacovigilacne,Dr.HirenR1.pptx
pharmacovigilacne,Dr.HirenR1.pptx
 
WHO international drug monitoring programme.pptx
WHO international drug monitoring programme.pptxWHO international drug monitoring programme.pptx
WHO international drug monitoring programme.pptx
 
Pharmacovigilance (pv)
Pharmacovigilance (pv)Pharmacovigilance (pv)
Pharmacovigilance (pv)
 
Haemovigilance
HaemovigilanceHaemovigilance
Haemovigilance
 
Pharmacovigilance
Pharmacovigilance Pharmacovigilance
Pharmacovigilance
 
pharmacovigilance pdf (1)
pharmacovigilance pdf (1)pharmacovigilance pdf (1)
pharmacovigilance pdf (1)
 
Pharmacovigilance pdf (1)
Pharmacovigilance pdf (1)Pharmacovigilance pdf (1)
Pharmacovigilance pdf (1)
 
Pharmacovigilance of Natural Drugs- Durgashree Diwakr
Pharmacovigilance of Natural Drugs- Durgashree  DiwakrPharmacovigilance of Natural Drugs- Durgashree  Diwakr
Pharmacovigilance of Natural Drugs- Durgashree Diwakr
 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reporting
 
Market Access Database Spain 2013
Market Access Database Spain 2013Market Access Database Spain 2013
Market Access Database Spain 2013
 
Belgium Regulatory Agency for New Drug Submissions 2014
Belgium Regulatory Agency for New Drug Submissions 2014Belgium Regulatory Agency for New Drug Submissions 2014
Belgium Regulatory Agency for New Drug Submissions 2014
 
Minimum requirements for a functional pharmacovigilance system
Minimum requirements for a functional pharmacovigilance systemMinimum requirements for a functional pharmacovigilance system
Minimum requirements for a functional pharmacovigilance system
 

Recently uploaded

Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxsiddharthroy26587
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxsiddharthroy26587
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptxMrStavanUdayKadam
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 

Recently uploaded (20)

Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptx
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptx
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 

Anvisa gudelines

  • 1. ANVISA National Health Surveillance Agency PREPARED BY; GUIDED BY; ANKIT GOTECHA Dr. TEJAL MEHTA 13MPH101 PHARMACEUTICS SEM 1 (M-PHARM) PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACEUTICS
  • 2. Introduction • ANVISA is regulatory body of BRAZIL. Brazil is biggest country of South America. Some of the small countries nearby Brazil are following the rules according to ANVISA. • ANVISA means “Agencia Nacional de Vigilancia Sanitaria”. This abbreviation is in Portuguese language. In English, it means “National Health Surveillance Agency” or sometimes it is written as “Brazilian Health Surveillance Agency”. • ANVISA is established on 26th January, 1999. Thus it does not have long historical backgrounds. • To get information about ANVISA, one has to open the website www.anvisa.gov.br. The website will open in Portuguese language first.
  • 3. BACKGROUND • The National Health Surveillance Agency was established in 1999 by president Fernando Henrique Cardoso. Linked to the Ministry of Health, the agency coordinates: – The National Sanitary Surveillance System – The National Program of Blood and Blood Products – The National Program of Prevention and Control of Hospital Infections
  • 4. • Anvisa's Mission – "To protect and promote health, ensuring the hygiene and safety of products and services and taking part in developing access to it." • Values – Transparency – Knowledge (as a springboard for action) – Cooperation • Vision – To be an agent for transformation of the decentralized sanitary surveillance system, within a network, holding a distinct position, legitimized by the population, as regulator and promotor of social well-being.
  • 5. • ANVISA is responsible for – monitoring drug prices – prices of medical devices – control and inspection of smoking products – technical support in granting of patents by the National Institute of Industrial Property. – protection of the health of the population by exercising sanitary control over production – marketing of products and services subject to sanitary surveillance, controlling ports, airports and borders – linked to the Brazilian Ministry of Foreign Affairs and foreign institutions over matters concerning international aspects of sanitary surveillance.
  • 6. ANVISA is a part of NSSS • National System of Sanitary Surveillance (NSSS) is an organization of Brazil whose responsibility is – To keep a watch over certain professional activities – To put a stop to charlatanism – To inspect ships, cemeteries and places where food was on sale to the public.
  • 7. • The federal, state and municipal units of this sanitary surveillance are: – National Agency for Sanitary Surveillance (ANVISA) – The National Council of State Health Secretaries (CONASS) – The National Council of Municipal Health Secretaries (CONASEMS) – The State, Federal District and Municipal Sanitary Surveillance Centers (VISAS) – The Central Public Health Laboratories (LACENS) – The National Institute for Quality Control in Health (INCQS) – The Oswaldo Cruz Foundation (FIOCRUZ) – The State, District and Municipal Health Councils
  • 9. National System of Sanitary Surveillance • In this section, you will find the addresses (in portuguese) of the federal, state and municipal units of sanitary surveillance that make up the National System of Sanitary Surveillance.
  • 10. Generic Drugs • FAQs section • Industry – – In this section, industry professionals can obtain information about Brazil's Generic Drugs Policy. – If your company wishes to apply for registration of a generic drug, whose reference drug has not yet been informed by ANVISA, please make a formal request to the Office of Generic Drugs. – Pharmaceutical equivalence and bioequivalence tests needed for registering generic drugs can only be carried out by reference centers duly authorized by ANVISA. • Legislation – Rules and documents related to regulation and registration of drugs in Brazil. Various Guidelines different categories are given.
  • 11. Medicine Bioavailability Bioequivalence Centers • • • • Application Forms for BA/BE centers Certification for Medicine Bioavailability/Bioequivalence Centers Renewal of Certification for Medicine BA/BE centers Centers for carrying out BA/BE shall observe the rules and technical regulations in force. • BA/BE Good Practices Manual is given in two volumes
  • 12. Travelers Information • This section is covered under a specific part of ANVISA related to Airport and Border regulation. Any new visitor of Brazil has to take Vaccine against YELLOW FEVER at least 10 days before his arrival to Brazil. And on arrival he has to show “International Certificate of Vaccination (ICV)”. • If he had taken Vaccine against yellow fever, before 10 years, then he has to take it again a booster dose.
  • 13. • Anvisa's Public Health Care Centers and Vaccination Rooms (in Portuguese) are ready to provide the vaccine and to issue the International Certificate of Vaccination (ICV), which is yellow. • Every person vaccinated in one of the Sanitary Units of the Unified Health System (SUS) receives the National Certificate of Vaccination, which is white and accepted in the whole country. • If, after that, you need the ICV, you should go to a Public Health Care Center or to a Vaccination Room of ANVISA to copy the National Certificate data to the International one.
  • 14. Severe Acute Respiratory Syndrome • In Brazil, there may be probability of getting Severe Acute Respiratory Syndrome (SARS) disease, similar to yellow fever. Thus, ANVISA had provided information on website for it. They had provided WHO website link for direct information.
  • 15. OFFICES OF ANVISA • • Advisory Council Office of Ombudsman
  • 16. ADVISORY COUNCIL • It monitors and follows up the development of activities carried out by ANVISA. Council comprise of Representatives from… – Public Administration Institutions – Organized Civil Society – Scientific Community • The main function of advisory council is to provide information upon request by any citizen, patient, industrialist or health professional on any topics. Unlike other well known regulatory bodies, ANVISA does not have specific offices for each topic to provide specific information only. It has a general functioning common Advisory council.
  • 17. OFFICE OF OMBUDSMAN • It is an independent body for direct communication of Citizens or Institutes to attend the Complaints. • It is characterized by impartiality and transparency. • It has no direct or indirect linking with ANVISA. It is regulated directly under the Brazilian ministry of health. • It Start action against complaints within 2 days, if appropriate.
  • 18. Regulations by ANVISA • • • • • • • • • • • • • • • Blood and blood products Cosmetics Drugs Generic Drugs Food Health services International Affairs Market regulations Medical devices Pharmacovigilance Ports, airports and borders REBLAS – Brazilian network of Analytical Laboratory Sanitizing Products Tobacco Toxicology
  • 20. REGISTRATION OF NEW DRUG • Registration procedure of new drug is divided in mainly 3 parts as follows… 1. Pre-registration measures • Protocol for Clinical study 2 Registration • Documents to be submitted • Protocol for the new drug • Protocol for import of new drug 3 Post-registration • Alteration in Registration, Renewal of Registration  Thus, these three parts can be considered similar to IND, NDA and Supplementary NDA as per US FDA.
  • 21. I. Pre-registration measures • In case of a new national drug product, the protocols of the clinical studies and the results or current status of the studies in compliance with the legislation in force has to be submitted. • In case of a new imported drug product that will undergo phase III clinical studies in Brazil, the study protocol and the results or current status of the studies in compliance with the legislation in force has to be submitted. • Whenever phase III will take place with a new product manufactured in the country, pre-notification for the production of pilot batch according to the GUIDE FOR THE NOTIFICATION OF PILOT BATCHES OF MEDICINES has to be submitted.
  • 22. II. Registration 1. Documents to be submitted • • • • Registration petition forms Proof of payment of Sanitary Surveillance Inspection copy of the company’s Operation License Technical Responsibility Certificate by the Regional Pharmacy Council • Copy of the notification protocol of pilot batch production • Good Manufacturing Practices certificate (GMP) emitted by ANVISA
  • 23. 2. Protocol for the new drug • General data: package insert text, label etc… • Expiry date by Stability studies • All Toxicity study reports • Clinical trial data with statistical treatments • For Combination – Maximum 3 is allowed for oral or injectable preparations. Four combinations are allowed only if the fourth ingredient is caffeine.
  • 24. • Retail Price: if the product is available in other market then applicator has to submit retail price of product to consumer. If product is not available anywhere, and first time registered in Brazil, then has to submit the Proposed retail cost of new drug product. • Physico-Chemical parameters of drug • Synthesis route (all reagent, solvent, condition) • Pharmacodynamic parameters • Pharmacokinetic parameters • Production Report(Batch size ,methods and equipments used) • Q.C. of raw material and finished products
  • 25. 3. Protocol for the import of new drug  GMP of importing country or Inspection by ANVISA.  Documentation is allowed in Portuguese, English or Spanish language.  Label, Package Insert must be in Portuguese (Brazilian) language  Official Documents like certificates given by importing country, if it is in foreign language that must be translated with Legal translator only.  In some cases, applicator wants to import Bulk drug from foreign and then Pack the product in Brazil. In such cases, Expiry Date must be counted from Manufacturing date in foreign, and not the packaging date in Brazil  Additionally all document should be submitted in CD
  • 26. III. Post-registration measures • Any registration changes shall follow the procedures specified in the GUIDE FOR MAKING POST-REGISTRATION ALTERATIONS AND INCLUSIONS IN MEDICINES. • ANVISA may undertake a control analysis of commercialized batches in official laboratories in order to monitor the quality and conformity of the drug with the drug registered. Whenever necessary, ANVISA may request that the companies train their technicians in order to enable them to undertake this monitoring.
  • 27. TECHNICAL REGULATION OF GENERIC DRUGS Definition: • Generic drug product is similar to a reference or innovator product, expected to be interchangeable with latter, usually produce after expiration or waiver of patent protection or of other exclusive rights, and its effectiveness, safety and quality had been already proven. • Registration procedure for Generic drug is similar to new drug registration. – Pre registration measures – Registration – Post registration
  • 28. Additional Requirements in registration includes… • Pharmaceutical Equivalence : Generic and Reference • If anyone of Generic or Reference is Coated tablet, prove that coating does not present Gastro-protection • Bioequivalence study in Laboratories duly authorized by ANVISA • Exemption of Bioequivalence study – Based on comparison of dissolution profile – For BCS Class I product – High solubility & permeability
  • 29. Medicines NOT accepted as GENERIC • Parenteral that don’t contain API like WFI, glucose solution, NaCl solution, electrolytes solution etc. • Biological products: Blood, Plasma products • Products obtained through Biotech except antibiotics • Herbal drug products • Vitamins &/or Mineral salts • Antiseptics for Hospital use • Endogenous Hormones of oral use • Products with Diagnostic purpose and Radiological contrasts • Some of OTC products
  • 30. Similar Drugs • Similar drugs are similar to Reference Drug product. It has Same Concentration, Dosage Form, Route of Administration, Strength ,Therapeutic action, but it only Differs in Size, Form of product, Packaging, Labeling, Expiry date, Excipients, Vehicles, and it is mainly identified by Trade Mark / Brand Name. • The advantage of similar drug is that it can be Dispense in place of Reference drug, unless denied by Doctor in written prescription.  How to identify the types of drugs in the Brazilian market: generic and branded? • Generic drug package / box contain phrase“ Generic Drug Law 9.787/99 “ • Generic will be identified in blue large letter “ G “ printed over a yellow emblem located in the lower part of the package which carry the product.
  • 31. Harmonisation of already registered drugs • ANVISA had introduced some modification in Registration procedures and Documents after 1st December 2004. • Drugs Registered before this date, has to submit information or data or documents related to drug, for harmonization with Newer Registered drug products
  • 32. Homeopathic drugs • Registration of Homeopathic drugs is valid upto 5 years. • For Injectables Homeopathic medicines, applicator has to submit Risk/Benefit compared with oral presentation of same product • Combination of any synthetic/ semi-synthetic/ biological product/ vitamins/ mineral salts/ herbal along with homeopathic is forbidden. Registration EXEMPTED for… • Simple drug product (Single Ingredient) • Without trademark or brand name • Manufacturing as per Brazilian Homeopathic Pharmacopoeia • Or in official compendia recognized by ANVISA
  • 33. Registration REQUIRED for… • Simple or Compound (2 or more Ingredient) • With trademark and brand name • whose formulation is composed of substances of verified therapeutic action described in the homeopathic drug product literature, official compendia, clinical studies or indexed journals and manufacturing procedures are as per Brazilian Homeopathic Pharmacopoeia
  • 34. GITE :List of specified therapeutic group and indications • • • • • Drugs described in GITE can be sold OTC Parentrals can not sold OTC (can not sell without Prescription) Drugs not listed in GITE can not sell without PRESCRIPTION. Any NEW DRUG, not to be sold under GITE If New Drug has minimum 5 years experience in USA or European market (with FDA or EMEA approval), and if it comes under GITE list, applicator may request to classify it as OTC product.
  • 35. In-vitro Diagnostic product ANVISA had classified in vitro diagnostic product into 4 classes as follows… Group A - Materials, devices, accessories & inputs for support of in vitro diagnostic products. Group B - for diagnosis of non-transmissible diseases. Group C - for diagnosis of infectious-contagious diseases, except those classified in Group D. Group D - for diagnosis of infectious-contagious diseases, sexually transmissible diseases or diseases spread by blood and blood products, as well as identification of blood groups, transfusion or preparation of blood products. Documents required for Registration… • Application form, Fee payment receipt • Copy of License or Permit for Manufacturing. • Label on the package of product, Instruction for Use • Technical Report • If imported, proof of Registration at competent health agency of importing country
  • 36. Cosmetics Four Categories – Hygiene Product - Soap, Shampoo, Tooth paste… – Cosmetic – Lipstick, Beauty Creams, Hair dye, Talc, Eye cosmetics, Nail cosmetics, Sunscreens, Oils… – Perfume – Children’s Product
  • 37. Level of Risk  Level 1 - Products with minimum risk  Level 2 - Products with potential risk • ANVISA is more conscious about cosmetics and thus a stringent rules and conditions are observed for cosmetics. • ANVISA gives a List of Allowed PRESERVATIVES (56 preservatives) with the following details of preservatives  Ref. No.  Substance Name  Maximum Allowable Concentration  Limitations  Condition of Use and Warning
  • 38. • Similar to preservatives, ANVISA also gives List of Allowed SUNSCREEN AGENTS (23) with similar details • Similarly, List of Allowed COLORING AGENT also given by ANVISA with following information…  Name or Number of Coloring Agent  Colour  Field of Application : 1 / 2 / 3 / 4  Other Limitation or Requirements • Field of Application is important to write for coloring agent. Classification is…  Permitted for All Cosmetics  For All Cosmetics, Except EYE Area  In Cosmetic which don’t come in contact with Mucosa  In Cosmetic which come in contact with Skin & Hair only Briefly
  • 39. List of RESTRICTIVE SUBSTANCES is also given by ANVISA. • Restrictive substances can be used with some established conditions and a specific warning for each individual restrictive substance should be printed on Label as per requirement. For such restrictive substance ANVISA had given following information…. • Ref. No. • Substance Name, Field of application or use • Maximum Allowable Concentration • Limitations and Requirements • Condition of Use and Warning
  • 40. List of PROHIBITED SUBSTANCE (412) is also given which cannot be used in cosmetic products. For Registration of Cosmetic, one has to enter the CODES in the application form given in guideline. • Codes are given for…  Cosmetic Product Group i.e. Toothpaste, Beauty cream  For Physical form i.e. Cream, Powder, Aerosol, Gel  Preservation Care  Primary Packaging i.e. Al tube, film, vial, jar  External Packaging i.e. plastic bag, cloth bag, case, jar
  • 41. GMP • As per the latest updates of “GMP Guide for Pharmaceutical Industry” approved by WHO’s World Health Assembly – WHA. • For Import of Drug in Brazil from country which is not included in MERCOSUL group requires Inspection of Drug Manufacturing unit by ANVISA. • MERCOSUL = Mercado Commun del Sul means “South Common Market” includes Argentina, Brazil, Chile, Paraguay & Uruguay (Group of Countries of South America) • All documents should be submitted in Portuguese language and Certified by the Brazilian Consulate, of the Country, where the Drug for Importation in Brazil is manufactured • GMP Certificate is Valid upto 1 year only.
  • 42. BA/BE Guidelnes Three stages of testing • Clinical Stage • Follow clinical studies as per Brazilian Pharmacopoeia • There should be not more than 5% difference in amount of Test and Reference API • Clinical researcher has to Quantify Unchanged API and Metabolites both. • Interval before 2nd dose – atleast 7 t1/2 of API • Weight of Volunteer should be +/- 15% of Normal Wt. • If t1/2 > 24 hrs. – Collect sample upto 72 hrs • Modified Release DF – Add Study with FOOD • Protocol approved & licensed by National Committee of Ethics in Research
  • 43. Analytical Stage • As per GCP, GLP ; using SOPs • Use Enough Std. for Calibration Curve • Chromatographic Methods are recommended • NMT 20% samples are Re-analyzed. • Loss of Samples shall be Justified • Results below LQL (Lower Quantification Limit) are considered as ZERO for statistical calculation.
  • 44. Statistical Stage • Calculate ASC, Cmax, Tmax. (ASC in Portuguese means AUC in English) • For Multiple doses… – Average Conc. In Steady state – Fluctuation Rate in Steady state • Submit – ANOVA, SSR, DF, F value, p value… • Necessary to build 90% Confidence Interval (CI) • For Low therapeutic Range API – 95% CI • Information about Software Program used.
  • 45. BA – BE GOOD PRACTICE MANUAL • • • • Volume I Module 1. Clinical Step Module 2. Analytical Step Module 3. Statistical Step • • • • Volume II Module 1. Micropipettes Module 2. Water for Chemical Analysis Module 3. Analytical Instrumentations
  • 46. OTHER FUNCTIONS OF ANVISA: REBLAS - Brazilian Network of Analytical Laboratories. It is the laboratory network and every analysis and clinical studies must be performing at any one of the REBLAS center approved by ANVISA. • Along with Drugs and Cosmetics, ANVISA have also regulation on… – Medical devices – Food – Tobacco products – Toxic products – Pharmacovigilance
  • 47. RECENT TRENDS OF ANVISA: • Launched the project to prevent the resistance against Antibiotic drugs • The site is among the ten best in two categories of the iBest Awards. ANVISA’s site is among the ten finalists in two categories i.e. “Government” and “Health and Well-being” • Launched the project to prevent the resistance against Antibiotic drugs.
  • 48. INDIAN PHARMA IN BRAZILIAN MARKET: Prominent product exporters: • Zydus Cadila • Torrent Pharmaceuticals • Dr. Reddys Labs • Ranbaxy Pharmaceuticals • Intas Pharmaceuticals • Sun Pharmaceuticals
  • 49. Major Drugs exported: • Losartan Potassium • Zolpidem tartarate • Alprazolam • Enalapril Maleate • Nortryptiline • Carbamazepine • Clonazepam • Fluconazole • Fluoxetine, etc.
  • 50. ANVISA approved CROs in Ahmedabad: • • • • • • • • Accutest BioArc Research Labs Zydus Research Center (ZRC) Torrent Research Center (TRC) Cadila Pharma Lambda Research Center Veeda Research Center Synchron Research Labs